Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01001 in Adults With Moderate to Severe Atopic Dermatitis
NCT06277245Phase 3Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zemprocitinib in atopic dermatitis (AD) (4 arms), sponsored by Lynk Pharmaceuticals. Primary endpoints: Eczema Area and Severity Index 75% reduction at 16 weeks and Investigator's Global Assessment score of 0 or 1 at 16 weeks. Started Feb 2024; status: completed.
02
Drugs
zemprocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06277245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277245.